• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

曲氟尿苷及其主要代谢物在大鼠和犬体内的药代动力学

Pharmacokinetics of triflusal and its main metabolite in rats and dogs.

作者信息

Ramis J, Mis R, Forn J

机构信息

Research Center, J. Uriach & Cia, S.A. Barcelona, Spain.

出版信息

Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):261-8. doi: 10.1007/BF03189970.

DOI:10.1007/BF03189970
PMID:1823869
Abstract

The methods for determining plasma concentrations of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) that have been described, do not distinguish between the drug and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid). In the present study, we have developed a new analytical technique based on HPLC that enabled us to carry out a pharmacokinetic study of the drug and its metabolite in animals. An intravenous or oral dose of 50 mg/kg was administered to male Sprague-Dawley rats, and 15 mg/kg was administered to beagle dogs. Plasma levels of triflusal and HTB were determined. In rats, triflusal was quickly eliminated from plasma with a biological half-life (t1/2) of 2.7 min and a clearance (Cl) of 73.4 (ml/kg)/min. The elimination of HTB was much slower with a t1/2 of 21.5 h and a Cl of 5.1 (mg/kg)/h. The maximum concentration (Cmax) of triflusal in rats after an oral administration was 8.1 +/- 2.0 micrograms/ml reached between 2.5 and 10 min. The Cmax of HTB was 237.7 micrograms/ml and was achieved at 0.7 h. The bioavailability of triflusal in rats was only 10.6% while the bioavailability of HTB was more than 100% indicating an important first pass effect. In dogs the t1/2 of triflusal was 14.4 +/- 5.9 min and the Cl was 25.1 +/- 4.7 (ml/kg)/min. HTB was also eliminated very slowly with a t1/2 of 71.1 +/- 12.5 h and a Cl of 2.4 +/- 0.3 (ml/kg)/h. The Cmax of triflusal in dogs was 13.3 +/- 2.9 micrograms/ml and was reached after 19.2 +/- 6.1 min (tmax).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

已描述的测定曲氟柳(2 - 乙酰氧基 - 4 - 三氟甲基苯甲酸)血浆浓度的方法,无法区分该药物及其主要代谢物HTB(2 - 羟基 - 4 - 三氟甲基苯甲酸)。在本研究中,我们开发了一种基于高效液相色谱的新分析技术,使我们能够在动物体内对该药物及其代谢物进行药代动力学研究。给雄性斯普拉 - 道利大鼠静脉注射或口服50mg/kg的剂量,给比格犬口服15mg/kg的剂量。测定曲氟柳和HTB的血浆水平。在大鼠中,曲氟柳从血浆中快速消除,生物半衰期(t1/2)为2.7分钟,清除率(Cl)为73.4(ml/kg)/分钟。HTB的消除则慢得多,t1/2为21.5小时,Cl为5.1(mg/kg)/小时。大鼠口服给药后曲氟柳的最大浓度(Cmax)为8.1±2.0微克/毫升,在2.5至10分钟之间达到。HTB的Cmax为237.7微克/毫升,在0.7小时时达到。曲氟柳在大鼠中的生物利用度仅为10.6%,而HTB的生物利用度超过100%,表明存在重要的首过效应。在犬中,曲氟柳的t1/2为14.4±5.9分钟,Cl为25.1±4.7(ml/kg)/分钟。HTB的消除也非常缓慢,t1/2为71.1±12.5小时,Cl为2.4±0.3(ml/kg)/小时。犬中曲氟柳的Cmax为13.3±2.9微克/毫升,在19.2±6.1分钟(tmax)后达到。(摘要截短至250字)

相似文献

1
Pharmacokinetics of triflusal and its main metabolite in rats and dogs.曲氟尿苷及其主要代谢物在大鼠和犬体内的药代动力学
Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):261-8. doi: 10.1007/BF03189970.
2
Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.单次口服给药后,健康受试者中曲氟尿苷及其主要代谢物HTB的药代动力学。
Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):269-73. doi: 10.1007/BF03189971.
3
Pharmacokinetics of triflusal after single and repeated doses in man.
Int J Clin Pharmacol Ther Toxicol. 1990 Aug;28(8):344-9.
4
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.曲氟尿苷的一种代谢物(2-羟基-4-三氟甲基苯甲酸)与大鼠和人体血清蛋白的结合情况。
Eur J Clin Pharmacol. 1992;42(2):175-9. doi: 10.1007/BF00278480.
5
Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Drug Res (Stuttg). 2014 May;64(5):263-8. doi: 10.1055/s-0033-1357180. Epub 2013 Oct 8.
6
Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.健康志愿者中曲氟尿苷主要代谢产物HTB进入脑脊液的情况。
Eur J Clin Pharmacol. 2005 Apr;61(2):103-11. doi: 10.1007/s00228-004-0887-0. Epub 2005 Feb 12.
7
Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.健康志愿者中两种曲氟司特胶囊口服制剂的生物等效性。
Arzneimittelforschung. 2008;58(6):283-7. doi: 10.1055/s-0031-1296508.
8
Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.健康受试者中曲氟尿苷口服溶液与曲氟尿苷胶囊的比较生物利用度研究。一项单中心、随机、双向交叉、开放标签的I期研究。
Arzneimittelforschung. 2010;60(1):36-41. doi: 10.1055/s-0031-1296246.
9
Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.食物对健康受试者中曲氟尿苷及其主要活性代谢物2-羟基-4-三氟甲基苯甲酸药代动力学的影响。
Int J Clin Pharmacol Ther. 2015 Mar;53(3):272-6. doi: 10.5414/CP202229.
10
Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Dec 25;798(2):257-64. doi: 10.1016/j.jchromb.2003.09.049.

引用本文的文献

1
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.水杨酸酯的4-三氟甲基衍生物对人星形细胞瘤细胞核因子κB依赖性转录的影响。
Br J Pharmacol. 2001 Jan;132(2):547-55. doi: 10.1038/sj.bjp.0703820.
2
4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation.水杨酸酯的4-三氟甲基衍生物、曲氟尿苷及其主要代谢物2-羟基-4-三氟甲基苯甲酸是核因子κB激活的有效抑制剂。
Br J Pharmacol. 1999 Mar;126(6):1359-66. doi: 10.1038/sj.bjp.0702441.
3

本文引用的文献

1
[Pharmacokinetic study of triflusal (UR-1501)].
Arch Farmacol Toxicol. 1981 Apr;7(1):11-2.
2
[Distribution and metabolism of triflusal].[曲氟司特的分布与代谢]
Arch Farmacol Toxicol. 1982 Dec;8(3):197-200.
3
Intravenous arachidonate-induced respiratory distress: comparative study of three in vivo models for the measurement of antithrombotic activity.静脉注射花生四烯酸盐诱导的呼吸窘迫:三种用于测量抗血栓活性的体内模型的比较研究。
J Pharmacol Methods. 1982 May;7(3):231-8. doi: 10.1016/0160-5402(82)90039-0.
Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
单次口服给药后,健康受试者中曲氟尿苷及其主要代谢物HTB的药代动力学。
Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):269-73. doi: 10.1007/BF03189971.
4
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.曲氟尿苷的一种代谢物(2-羟基-4-三氟甲基苯甲酸)与大鼠和人体血清蛋白的结合情况。
Eur J Clin Pharmacol. 1992;42(2):175-9. doi: 10.1007/BF00278480.
4
Gastrointestinal and hepatic first-pass effects of salicylamide in rats.水杨酰胺在大鼠体内的胃肠道和肝脏首过效应。
J Pharm Pharmacol. 1983 Oct;35(10):687-9. doi: 10.1111/j.2042-7158.1983.tb02871.x.
5
Gastrointestinal and hepatic first-pass metabolism of aspirin in rats.
J Pharm Pharmacol. 1982 Mar;34(3):176-80. doi: 10.1111/j.2042-7158.1982.tb04216.x.
6
Influence of the route of administration on the area under the plasma concentration-time curve.给药途径对血浆浓度-时间曲线下面积的影响。
J Pharm Sci. 1969 Jan;58(1):71-5. doi: 10.1002/jps.2600580114.
7
Effects of triflusal in patients with prosthetic heart valves.
Clin Ther. 1985;7(3):357-60.
8
Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anesthetized rats.
Methods Find Exp Clin Pharmacol. 1987 Jan;9(1):13-7.
9
Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.
Arch Int Pharmacodyn Ther. 1986 Nov;284(1):155-65.
10
[Inhibitory effect of 2-acetoxy-4-trifluoromethylbenzoic acid (triflusal) and aspirin on platelet aggregation in man and rat: in vitro study].
Therapie. 1977 May-Jun;32(3):337-44.